ChartRow logo
Share this page
DNTH
$72.09-3.27%
as of close, Oct 16, 2026
☾ AH $72.09 -3.27%
PeersMRNALLYMDTUNHJNJTMO

Dianthus Therapeutics Inc. trailing returns

How Dianthus Therapeutics Inc. (DNTH) has performed over the last day, week, month and year, over 5 years, and since inception, through October 16, 2026 — price return and dividends side by side, with the worst drop inside each window.

Trailing returns by period#

To 2026-10-16. Price return + dividends = total return. Per year (CAGR) for windows of a year or more, with the cumulative total return beneath. Worst drop: the deepest fall in the price from a high inside the window, and when it bottomed.

PeriodPriceDivsTotalWorst drop
1 day-3.3%+0.0%-3.3%—
5 days-12.5%+0.0%-12.5%-12.5%Oct 16
1 month-29.7%+0.0%-29.7%-29.7%Oct 16
YTD+74.9%+0.0%+74.9%-37.8%Oct 16
1 year+100.3%+0.0%+100.3%-37.8%Oct 2026
5 years-7.7%+0.0%-7.7%-33.1%-95.7%Dec 2022
Since inception (2018)-13.1%+0.0%-13.1%-69.0%-98.2%Dec 2022

Growth of DNTH#

Actual level with dividends reinvested (solid); dashed lines are each window's constant-rate path from start to today.

  • 5 years-7.7%/year · -33.1%

Methodology#

Trailing returns measure from the closest close about N years before the latest close (2026-10-16). Cumulative return is the total change over the window; annualized return is the compound annual growth rate (CAGR), shown for windows of a year or more. Price return is the change in DNTH's closing price; total return reinvests dividends (from its split- and dividend-adjusted closes); the dividends column is the difference between the two. The worst drop is the largest fall in the closing price from a high to a later low inside the window, the way a drawdown is usually quoted. See the year-by-year returns for the calendar breakdown. Past performance does not predict future returns; not investment advice.

FAQ#

What is Dianthus Therapeutics Inc.'s return since inception?
Since 2018, Dianthus Therapeutics Inc. (DNTH) has compounded at about -13.1% a year — -69.0% in total.

More on Dianthus Therapeutics Inc.